Literature DB >> 7334446

Systemic effects of mydriatics in low weight infants.

T Rosales, S Isenberg, R Leake, S Everett.   

Abstract

Two-and-a-half percent phenylephrine eye drops were used in combination with 0.5% tropicamide for routine pupillary dilation in 10 low weight infants. Significant systolic blood pressure elevation was noted in eight of 10 infants. A matched control group dilated with cycloplegics alone did not show a significant rise in systolic blood pressure. The mean change in pupillary dilation in the study group was 3.9 mm compared with 3.1 mm in the control group. This difference is not statistically significant. We therefore recommend that cycloplegic agents alone be used for pupillary dilation in these high risk infants.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334446     DOI: 10.3928/0191-3913-19811101-11

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  5 in total

1.  Reduction in mydriatic drop size in premature infants.

Authors:  S Wheatcroft; A Sharma; J McAllister
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

Review 2.  Systemic and local tolerability of ophthalmic drug formulations. An update.

Authors:  F C Hugues; C Le Jeunne
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

Review 3.  Systemic reactions to ophthalmic drug preparations.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

4.  Systematic review of mydriatics used for screening of retinopathy in premature infants.

Authors:  Lisa Jean Kremer; David M Reith; Natalie Medlicott; Roland Broadbent
Journal:  BMJ Paediatr Open       Date:  2019-05-09

5.  Efficiency and safety of phenylephrine and tropicamide used in premature retinopathy: a prospective observational study.

Authors:  Atilla Alpay; Sılay Canturk Ugurbas; Cumhur Aydemir
Journal:  BMC Pediatr       Date:  2019-11-06       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.